AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings.
Approved in Europe, Zalviso delivers a 15 mcg sublingual dose of sufentanil via a novel preprogrammed device—providing an alternative to IV patient-controlled analgesia in the hospital. Zalviso is an investigational drug. It is not approved by the FDA. AcelRx makes no claims regarding the safety or effectiveness of Zalviso.
DSUVIA™ and Zalviso® were both developed using this proprietary sublingual technology.